Outcome Of Annual General Meeting Of May 19, 2020
May 20 2020 - 1:00AM
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
announces the results of the vote of its shareholders at the Annual
General Meeting (“AGM”) which took place on May 19, 2020, in
Marseille, France without the physical presence of its
shareholders. All resolutions were voted in accordance with the
Executive Board’s recommendations.
A total of 43,629,034 votes were cast out of a
total of 79,698,670 shares with voting rights, representing a
quorum of 55.300%.
These resolutions, the results of the votes and
other documents relating to the AGM are available in the Annual
General Meeting 2020 section of the Company’s website:
https://investors.innate-pharma.com/regulated-information/general-shareholders-meeting.
***The 2019 20-F
of the Company is available on its website.
***
During the meeting, Pascale Boissel was
appointed as a new member of the Supervisory Board and member of
the Audit Committee.
With more than 30 years of financial experience,
Mrs. Boissel is an expert in finance, audit, transactions, internal
control, growth management and restructuring operations. Her
experience has been represented in a variety of industries,
including: food and beverage (Danone), building materials (Lafarge
Holcim), education, and health and biotechnology. She began her
career in audit and corporate finance at PricewaterhouseCoopers
Paris. Mrs. Boissel is currently a financial consultant and
part-time CFO of Novadiscovery.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Switzerland, was approved by the FDA in September 2018. Lumoxiti is
a first-in class specialty oncology product for hairy cell
leukemia. Innate Pharma’s broad pipeline of antibodies includes
several potentially first-in-class clinical and preclinical
candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
|
|
For additional information, please
contact:
Investors Innate PharmaDanielle
Spangler Tel.: +1 917 499 6240
Danielle.Spangler@innate-pharma.com |
Media Innate Pharma Tracy Rossin
(Global/US) Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com |
|
|
Jérôme MarinoTel.: +33 (0)4 30 30 30
30investors@innate-pharma.com |
ATCG Press Marie Puvieux (France) Tel.: +33 (0)9
81 87 46 72 innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jul 2023 to Jul 2024